Real-World Clinical Efficacy of Food and Drug Administration-Approved Budesonide Oral Suspension Across Histologic, Endoscopic, and Symptomatic Outcomes.

Authors

Gustaf N Hendrick, Shi Chen, Stefani Aleman, Alexandra A Weir, Langley B Barnes, Sean S LaFata, Arjun K Juneja, Angelica R Lackey, Cassie B Almond, Shivani Desai, Ambika V Viswanathan, Gabriel L Sperling, Daniel Song, Christopher J Lee, Michelle S Russin, Natalie J Wilson, Trevor S Barlowe, Walker D Redd, Cary C Cotton, Craig C Reed, Evan S Dellon

Published in

Gastro hep advances. Volume 5. Issue 10. Pages 101070. Epub Jul 20, 2026.

Abstract

Though topical corticosteroids have long been used for the treatment of eosinophilic esophagitis (EoE), real-world data for the recently Food and Drug Administration-approved budesonide oral suspension (BOS) are lacking. We sought to determine the efficacy of BOS in a real-world cohort of EoE patients.
We conducted a retrospective cohort study of patients with EoE who were treated with BOS. Baseline characteristics, history, and procedural data were extracted from the medical record. We assessed endoscopic, histologic, and symptomatic responses for the endoscopy immediately preceding and following 12 weeks of BOS.
We identified 145 EoE patients prescribed BOS at our center since 2024 (mean age 35.4 years; 60% male), of whom 111 (77%) ultimately obtained insurance approval and 94 (65%) were able to fill their prescription. Post-treatment data were available for 48 patients. Compared to before BOS treatment, post-BOS patients were more likely to achieve a histologic response at all thresholds (eg, 73% vs 19% for <15 eos/hpf; P < .001) and endoscopic response (64% vs 22% for EoE Endoscopic Reference Score ≤2; P < .001), with associated significant reductions in peak eosinophil count (15.0 ± 30.6 vs 66.7 ± 71.8; P < .001) and total EoE Endoscopic Reference Score (2.0 ± 1.9 vs 3.9 ± 2.2; P < .001). Global symptom improvement was reported in 78%.
In this initial real-world cohort treated with the Food and Drug Administration-approved BOS, histologic response rates reflected those seen in BOS clinical trials. Symptoms and endoscopic findings improved in parallel. Because the majority of prescriptions could be filled and significant improvement was achieved compared to prior treatments, BOS should be considered when topical steroids are selected for EoE.

PMID:
42633174
Bibliographic data and abstract were imported from PubMed on 23 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.